Delving into the Latest Updates on Meningococcal Polysaccharide Vaccine, Group C with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Menomune-C

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Meningococcal Infections

Inactive Indication-

Originator Organization

Sanofi Pasteur, Inc.

Active Organization

Sanofi Pasteur, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (09 Dec 1999),

Meningococcal Infections

Regulation-

Login to view timeline

Purified meningococcal polysaccharides were administered to army recruits. No adverse reactions were observed in 145 men who received group C polysaccharide, and in 53 men who were injected with group A polysaccharide. Hemagglutinating and bactericidal activity developed in the sera of all individuals with the exception of two recruits injected with A polysaccharide.During the 6 wk period of observation, the proportion of unvaccinated recruits who acquired group C meningococci in the three companies studied was 38, 42, and 69 per cent. A significantly lower proportion of the individuals vaccinated with group C polysaccharide acquired group C meningococci; 4.6, 24, and 31 per cent respectively.

100 Deals associated with Meningococcal Polysaccharide Vaccine, Group C

Login to view more data